On Thursday, the S&P/ASX 200 Index (ASX: XJO) had a mildly positive session and finished the day a fraction higher. The benchmark index rose 0.1% to 8,773 points.
Will the market be able to bounce back from this on Friday and end the week on a high? Here are five things to watch:
ASX 200 expected to rise
The Australian share market looks set to edge higher on Friday despite a poor night in the United States. According to the latest SPI futures, the ASX 200 is expected to open 6 points higher this morning. On Wall Street, the Dow Jones was down 0.4%, the S&P 500 fell 0.5%, and the Nasdaq dropped 0.5%.
Oil prices rise
It could be a decent finish to the week for ASX 200 energy shares Santos Ltd (ASX: STO) and Karoon Energy Ltd (ASX: KAR) after oil prices pushed higher overnight. According to Bloomberg, the WTI crude oil price is up 0.4% to US$65.24 a barrel and the Brent crude oil price is up 0.45% to US$69.62 a barrel. Oil prices have been climbing this week on supply concerns.
Dividend payday
It is payday for shareholders of a number of ASX 200 shares on Friday. This includes financial services company AMP Ltd (ASX: AMP), iron ore miner Fortescue Ltd (ASX: FMG), insurer QBE Insurance Group Ltd (ASX: QBE), and supermarket giant Woolworths Group Ltd (ASX: WOW). The latter is rewarding its shareholders with a fully franked final dividend of 45 cents per share.
Gold price rises
ASX 200 gold shares Evolution Mining Ltd (ASX: EVN) and Northern Star Resources Ltd (ASX: NST) could have a decent finish to the week after the gold price pushed higher overnight. According to CNBC, the gold futures price is up 0.3% to US$3,780.6 an ounce. Traders were buying gold ahead of the release of key inflation data that could shape the US Federal Reserve's next interest rate moves.
Buy Telix shares
Telix Pharmaceuticals Ltd (ASX: TLX) shares could be cheap according to analysts at Bell Potter. This morning, the broker has retained its buy rating and $23.00 price target on the radiopharmaceuticals company's shares. It said: "Volatility in the TLX share price is set to continue, this time for positive reasons following the CMS decision to grant pass through pricing for Gozellix from 1 October. The decision to pursue this strategy (for a refresh on the pass through) has proven to be a master stroke by the company and one that that has shown its major competitor in the PSMA imaging market asleep at the wheel. The announcement has provided welcome relief for shareholders following a difficult year for TLX thus far in 2025, highlighted by the two CRLs."
